https://scholars.lib.ntu.edu.tw/handle/123456789/557704
標題: | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | 作者: | Wu Y.-L. Cheng Y. Zhou J. Lu S. Zhang Y. Zhao J. Kim D.-W. Soo R.A. Kim S.-W. Pan H. Chen Y.-M. Chian C.-F. Liu X. Tan D.S.W. Bruns R. Straub J. Johne A. Scheele J. Park K. CHIH-HSIN YANG Liu Z. Chen X. Wang M. Yu S. Zhang H. Fang J. Li W. Yang C.-H. Chang G.-C. Hsia T.-C. Yang C.-T. Wang C.-C. Cho B.C. Lee K.H. Kim Y.-C. An H.J. Woo I.S. Cho J.Y. Shin S.W. Lee J.-S. Kim J.-H. Yoo S.S. Kato T. Shinagawa N. Tan S.W.D. Ngo L.S.-M. Ratnavelu K. Ahmad A.R. Liam C.K. de Marinis F. Tassone P. Molla A.I. Calles Blanco A. Lazaro Quintela M.E. Felip Font E. Dingemans A.-M. Bui L. |
公開日期: | 2020 | 出版社: | Lancet Publishing Group | 卷: | 8 | 期: | 11 | 起(迄)頁: | 1132-1143 | 來源出版物: | The Lancet Respiratory Medicine | 摘要: | Background: We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or MET amplification having acquired resistance to EGFR inhibition. Methods: In this open-label, phase 1b/2, multicentre, randomised trial (the INSIGHT study), we enrolled adult patients (?18 years) with advanced or metastatic NSCLC, and Eastern Cooperative Oncology Group performance status of 0 or 1, from academic medical centres and community clinics in six Asian countries. In phase 1b, patients received oral tepotinib 300 mg or 500 mg plus gefitinib 250 mg once daily. In phase 2, patients with EGFR-mutant, T790M-negative NSCLC MET overexpression or MET amplification were randomly assigned (initially in a 1:1 ratio and then 2:1 following a protocol amendment) to tepotinib plus gefitinib at the recommended phase 2 dose or to standard platinum doublet chemotherapy. Randomisation was done centrally via an interactive voice-response system. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS) and safety. Subgroup analyses were preplanned in patients with high MET overexpression (IHC3+) or MET amplification (mean gene copy number ?5 or MET to centromere of chromosome 7 ratio ?2). Efficacy and patient characteristics were assessed on an intention-to-treat basis and safety was assessed for all patients who received at least one dose of study medication. Low recruitment led to early termination of phase 2, so all analyses are considered to be exploratory. This study is registered with ClinicalTrials.gov, NCT01982955, and the European Union Drug Regulating Authorities Clinical Trials Database, Eudra-CT 2016-001604-28. Findings: From Dec 23, 2013, to May 25, 2017, 18 patients were enrolled in phase 1b (n=6 in the 300 mg tepotinib group; n=12 in the 500 mg tepotinib group) and 55 patients in phase 2 (n=31 in the tepotinib plus gefitinib group; n=24 in the chemotherapy group). No dose-limiting toxicities were observed in phase 1b, so tepotinib 500 mg was used as the recommended phase 2 dose. In phase 2, survival outcomes were similar between groups: median PFS was 4·9 months in the tepotinib plus gefitinib group (90% CI 3·9–6·9) versus 4·4 months in the chemotherapy group (90% CI 4·2–6·8; hazard ratio [HR] 0·67, 90% CI 0·35–1·28). Median OS was 17·3 months in the tepotinib plus gefitinib group (12·1–37·3) versus 18·7 months in the chemotherapy group (15·9–20·7; HR 0·69, 0·34–1·41). PFS and OS were longer with tepotinib plus gefitinib than with chemotherapy in patients with high (IHC3+) MET overexpression (n=34; median PFS 8·3 months [4·1–16·6] vs 4·4 months [4·1–6·8]; HR 0·35, 0·17–0·74; median OS 37·3 months [90% CI 24·2–37·3] vs 17·9 months [12·0–20·7]; HR 0·33, 0·14–0·76) or MET amplification (n=19; median PFS 16·6 months [8·3–not estimable] vs 4·2 months [1·4–7·0]; HR 0·13, 0·04–0·43; median OS 37·3 months [90% CI not estimable] vs 13·1 months [3·25–not estimable]; HR 0·08, 0·01–0·51). The most frequent treatment-related grade 3 or worse adverse events were increased amylase (5 [16%] of 31 patients) and lipase (4 [13%]) concentrations in the tepotinib plus gefitinib group and anaemia (7 [30%] of 23 patients) and decreased neutrophil count (3 [13%]) in the chemotherapy group. Interpretation: Despite early study termination, in a preplanned subgroup analysis, our findings suggest improved anti activity for tepotinib plus gefitinib compared with standard chemotherapy in patients with EGFR-mutant NSCLC and MET amplification, warranting further exploration. Funding: Merck KGaA. ? 2020 Elsevier Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086410877&doi=10.1016%2fS2213-2600%2820%2930154-5&partnerID=40&md5=55bf725f5036d449bb9916aebae9c2e0 https://scholars.lib.ntu.edu.tw/handle/123456789/557704 |
ISSN: | 2213-2600 | DOI: | 10.1016/S2213-2600(20)30154-5 | SDG/關鍵字: | alanine aminotransferase; amylase; aspartate aminotransferase; creatinine; epidermal growth factor receptor; gefitinib; scatter factor receptor; tepotinib; triacylglycerol lipase; urea; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; gefitinib; MET protein, human; piperidine derivative; pyridazine derivative; pyrimidine derivative; scatter factor receptor; tepotinib; acne; adult; adverse event; anemia; Article; Asian; asthenia; cancer combination chemotherapy; cancer resistance; cancer survival; centromere; chromosome 7; constipation; decreased appetite; dermatitis; diarrhea; dizziness; female; gene amplification; gene dosage; gene overexpression; human; hypokalemia; immunohistochemistry; intention to treat analysis; leukocyte count; major clinical study; male; MET gene; multicenter study; nausea; neutropenia; neutrophil count; non small cell lung cancer; overall survival; paronychia; peripheral edema; phase 1 clinical trial; phase 2 clinical trial; priority journal; progression free survival; pruritus; rash; renal clearance; side effect; survival rate; survival time; treatment outcome; urea blood level; vomiting; aged; clinical trial; controlled study; disease free survival; drug effect; drug resistance; gene expression regulation; genetics; lung tumor; middle aged; mortality; mutation; non small cell lung cancer; pathology; prognosis; proportional hazards model; randomized controlled trial; risk assessment; survival analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。